West Pharmaceutical Services, Inc. WST
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 874.50M | 872.30M | 844.90M | 805.00M | 804.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 874.50M | 872.30M | 844.90M | 805.00M | 804.60M |
| Cost of Revenue | 527.10M | 543.10M | 548.50M | 501.10M | 510.30M |
| Gross Profit | 347.40M | 329.20M | 296.40M | 303.90M | 294.30M |
| SG&A Expenses | 108.80M | 112.00M | 99.50M | 107.50M | 101.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.60M | 1.50M | -2.20M | 400.00K | 300.00K |
| Total Operating Expenses | 652.60M | 676.30M | 661.60M | 630.80M | 628.80M |
| Operating Income | 221.90M | 196.00M | 183.30M | 174.20M | 175.80M |
| Income Before Tax | 272.00M | 186.20M | 183.50M | 165.40M | 174.00M |
| Income Tax Expenses | 58.00M | 32.20M | 44.70M | 33.30M | 34.00M |
| Earnings from Continuing Operations | 214.00M | 154.00M | 138.80M | 132.10M | 140.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 214.00M | 154.00M | 138.80M | 132.10M | 140.00M |
| EBIT | 221.90M | 196.00M | 183.30M | 174.20M | 175.80M |
| EBITDA | 267.80M | 242.20M | 228.50M | 221.20M | 218.80M |
| EPS Basic | 3.04 | 2.18 | 1.93 | 1.83 | 1.94 |
| Normalized Basic EPS | 2.00 | 1.78 | 1.64 | 1.57 | 1.55 |
| EPS Diluted | 3.02 | 2.15 | 1.92 | 1.82 | 1.92 |
| Normalized Diluted EPS | 1.99 | 1.76 | 1.63 | 1.56 | 1.55 |
| Average Basic Shares Outstanding | 70.40M | 70.80M | 72.00M | 72.30M | 72.20M |
| Average Diluted Shares Outstanding | 70.80M | 71.30M | 72.40M | 72.70M | 72.60M |
| Dividend Per Share | 0.22 | 0.22 | 0.22 | 0.22 | 0.21 |
| Payout Ratio | 7.24% | 10.19% | 11.38% | 11.96% | 10.79% |